Shorter colorectal cancer screening intervals may be appropriate for patients with higher fecal hemoglobin concentrations on fecal immunochemical testing.
If colon cancer blood tests eventually win FDA approval and Medicare reimbursement, their use could become more widespread. But first this approach needs to match up against the current standard.
With computer-aided detection, more adenomas were found, and there was a twofold reduction in missed adenomas for patients undergoing screening or surveillance colonoscopy in a new trial.